Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. entered into a private placement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to raise gross proceeds of approximately $50.0 million. The transaction covers 1,418,071 shares of common stock at $33.21 per share and pre-funded warrants to purchase up to 87,500 shares at $33.209 per warrant.
The pre-funded warrants are immediately exercisable at $0.001 per share on a cashless basis and include beneficial ownership limits of 4.99% or 9.99%, which can increase up to 19.99% with notice. Cue plans to use net proceeds to fund clinical development and for general corporate purposes. The closing is expected on July 13, 2026, subject to customary conditions, and the company agreed to register the resale of the securities within 30 days of closing.
Separately, under its 2026 Stock Incentive Plan, Cue granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao‑Lee Lin, 109,178 to the Chief Legal and Compliance Officer, and 81,884 to the Principal Accounting Officer, plus 21,800 RSUs to each non‑employee director.
Cue Biopharma, Inc. registers 551,724 shares of common stock for resale by Ascendant Health Sciences, Ltd. These 551,724 shares are issuable upon exercise of pre-funded warrants and are being registered for resale by the selling stockholder; the company will not receive proceeds from those resale transactions except nominal proceeds equal to the $0.001 cash exercise price per share for any Pre-Funded Warrants exercised for cash. The Pre-Funded Warrants were issued as partial consideration under a Securities Purchase Agreement dated April 30, 2026. As context, shares outstanding were 4,200,343 as of June 1, 2026, and the last reported sale price on June 17, 2026 was $26.73 per share.
Cue Biopharma, Inc. filed an initial Form 3 for officer Michael Vincent Meluzio, who serves as VP and Principal Accounting Officer. The filing reports that he is an officer but does not list any equity transactions or current holdings in either common stock or derivatives.
Cue Biopharma, Inc. filed an initial Form 3 showing that Chief Legal Compliance Officer and Corporate Secretary Ray Sumita holds 54,589 shares of common stock directly. The filing also reports a stock option covering 109,179 shares of common stock at an exercise price of $30.42 per share, expiring on May 1, 2036.
According to the footnote, this stock option becomes exercisable in equal quarterly installments over four years measured from May 1, 2026, meaning vesting is spread over that period rather than all at once.
Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of stock options covering 1,626 shares of common stock. The options have an exercise price of $21.90 per share and expire on May 29, 2036.
The award vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in eight equal quarterly installments. Following this grant, Camardo holds stock options for 1,626 underlying shares directly as reported in this filing.
Cue Biopharma, Inc. filed an initial insider ownership report for Daniel A. Camardo, who is identified as a director of the company. This Form 3 data shows no reported buy, sell, or other share transactions and no derivative positions for him in this filing snapshot.
Cue Biopharma, Inc. director and Chief Executive Officer Shao-Lee Lin reported indirect purchases of derivative securities tied to the company’s common stock. A trust associated with Lin acquired 45,453 common stock warrants with an exercise price of $11.00 per share and 90,906 pre-funded warrants with an exercise price of $0.001 per share on June 1, 2026.
These positions were obtained under a securities purchase agreement entered on April 30, 2026, in a private placement that closed on May 4, 2026. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following stockholder approval of the underlying common stock issuance at the company’s Special Meeting of Stockholders in accordance with Nasdaq listing rules.
Cue Biopharma, Inc. reported results of a special stockholder meeting held on June 1, 2026. Stockholders approved the issuance of common shares upon exercise of warrants issued in May 2026 in connection with a licensing transaction and related private placement, satisfying Nasdaq Listing Rule 5635(a), (c) and (d).
They also approved the company’s 2026 Stock Incentive Plan, which will govern future equity awards to employees and other eligible participants. A proposal to allow adjournment of the meeting, if needed, was approved but ultimately not required because the main proposals received sufficient support.